A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers
Latest Information Update: 11 Aug 2022
At a glance
- Drugs Bevacizumab (Primary)
- Indications Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors mAbxience
- 09 Aug 2021 Result (n=114) assessing pharmacokinetic equivalence in healthy male volunteers between MB02 and the reference bevacizumab, as well as comparable safety and immunogenicity profile, published in the British Journal of Clinical Pharmacology.
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.
- 27 Jan 2020 New trial record